Drugs / CB-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05722418 | Feb 2023 → Dec 2027 expected | refractory plasma cell neoplasm | Caribou Biosciences, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Caribou Biosciences, Inc. | Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting cariboubio.com ↗ |
| 2026-05-12 | Caribou Biosciences, Inc. | Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting cariboubio.com ↗ |
| 2026-03-31 | Caribou Biosciences, Inc. | Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy cariboubio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05722418 ↗ |